Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewThe new amendment proposal on European IVDR regulation extends the transition period for n...
According to the amendment proposal, the transition period is only extended for manufacturers with ongoing contracts with notified bodies.
-
EventBio Asia Taiwan
-
EventON Helix
-
EventWorld Bio Markets
-
EventMEDTECH SUMMIT
-
EventThe Medtech Forum
-
-
-
NewAseBio, AEPLA, ANOVE, and the ANTAMA Foundation urge European legislators to vote in favor...
The Parliament is expected to adopt its mandate during the plenary session on February 7, 2024, after which it will be ready to commence negotiations with EU Member States.
-
Press releaseAseBio, AEPLA, ANOVE, and the ANTAMA Foundation urge European legislators to vote in favor...
The Parliament is expected to adopt its mandate during the plenary session on February 7, 2024, after which it will be ready to commence negotiations with EU Member States. It is crucial not to miss
-
NewGENESIS Tech Transfer Boost incorporates a new investment partner, PINONO S.L.
GENESIS Tech Transfer Boost is an investment vehicle created in 2022 that invests in the field of Biomedicine.
-
EventISCT 2024
-
NewORYZON to provide corporate progress updates at several events in February-March
Keystone Symposia Epigenetic Mechanisms and Cancer Treatment; Bio-Neuroscience; 17º Annual European Life Sciences CEO Forum and BIO-Europe Spring 2024.
-
CompanyMATCH BIOSYSTEMS
-
Press release
Biotechnology is revolutionizing the present and future of the fight against cancer
Immunotherapy, gene therapy, the study of mRNA and its potential application in vaccines, nanotechnology, liquid biopsy, the development of specific biomarkers, and CAR-T cells are just a few examples
-
NewDrug Discovery, Early Diagnosis, and New Treatments: This is how biotechnology has changed...
On World Cancer Day, we take a look at the role that biotechnology has played in recent years in crucial areas related to cancer.
-
NewGENESIS Tech Transfer Boost invests €50,000 in the start-up Affirma Biotech
Affirma Biotech develops immune system activation compounds for the treatment of infectious diseases.
-
New3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European...
Through this combination, the Group will become one of the main independent European bio-CDMOs, with gross sales above €75m.
-
New#NewAseBioMember | “AseBio is a meeting place for companies in the bio sector, which can a...
Meet Afarvi Sistemas, our new member. We talked to its Juan Antonio de la Cuerda Pérez, responsable de Desarrollo de Negocio y Marketing.
-
CompanySavana
-
